secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001493152-24-002061
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Therapeutics appoints Steven Mintz to Board of Directors, effective Jan 8, 2024
--------------------------------------------------------------------------------

- Board of Directors expanded to four members; Steven Mintz appointed as director effective Jan 8, 2024.
- Mintz serves on Audit, Compensation, and Nominating committees. He is a financial consultant and director at Portage Biotech.
- Receives cash fee of $34,331 and options to purchase 63,756 shares of AgeX common stock for 2024 service.
- Additional cash fee of $9,809 for Audit Committee chair role. Fees and options vest quarterly through Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224002061/0001493152-24-002061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224002061/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-002061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer